| Literature DB >> 31412673 |
Perrine André1, Fabienne Laugerette2, Catherine Féart3.
Abstract
(1) Background: Nutrition is a major lifestyle factor that can prevent the risk of cognitive impairment and dementia. Diet-induced metabolic endotoxemia has been proposed as a major root cause of inflammation and these pathways emerge as detrimental factors of healthy ageing. The aim of this paper was to update research focusing on the relationship between a fat-rich diet and endotoxemia, and to discuss the potential role of endotoxemia in cognitive performances. (2)Entities:
Keywords: Alzheimer’s disease; dementia; dietary fat; endotoxemia; high-fat; humans; lipopolysaccharide; nutrition
Mesh:
Substances:
Year: 2019 PMID: 31412673 PMCID: PMC6722750 DOI: 10.3390/nu11081887
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Selective evidence on the association between a single high-fat meal and metabolic endotoxemia.
| Clinical Trials | |||||
|---|---|---|---|---|---|
| Reference | Sample Characteristics | Endotoxemia Assessment | Nutritional Characteristics | Analysis Design | Results |
| Lyte JM. et al., Lipids Health Dis, 2016 [ | 20 healthy subjects (mean age 25 y, 60% men) | Serum LPS quantified by LAL | Four meals (35% fat provided from n-3 PUFA (fish oil), 35% fat provided from n-6 PUFA (grapeseed oil), 35% fat provided from SFA (coconut oil) and 20% fat (olive oil, control diet)) | Randomized single-blind crossover study | |
| Al-Disi DA. et al., Nutrients, 2015 [ | 92 lean controls (mean age 24 y), 24 overweight or obese (mean age 32 y) and 50 T2DM (mean age 42 y) subjects, all women | Serum LPS quantified by LAL | High-fat meal (whipping cream with 75 g fat, 5 g carbohydrate and 6 g protein per m² body surface) | Randomized controlled trial | |
| Vors C. et al., J Clin Endocrinol Metab, 2015 [ | 8 normal-weight (mean age 29 y) and 8 obese (mean age 31 y) subjects, all men | Plasma LPS quantified by LAL | Mixed meals containing 10 or 40 g fat (69% SFA, 28% MUFA and 3% PUFA) | Randomized crossover study | |
| Schwander F. et al., J Nutr, 2014 [ | 19 normal-weight (mean age 41 y) and 18 obese (mean age 44 y) subjects, all men | Plasma LPS quantified by LAL | 500, 1000 and 1500 kcal of a high-fat meal (61% fat) | Randomized crossover study | |
| No difference in the dose-response of postprandial LPS between normal-weight and obese | |||||
| Harte AL. et al., Diabetes Care, 2012 [ | 9 non-obese (mean age 40 y, 50% men), 15 obese (mean age 44 y, 50% men), 12 impaired glucose tolerance (IGT, mean age 42 y, 58% men) and 18 T2DM (mean age 45 y, 61% men) subjects | Serum LPS quantified by LAL | High-fat meal (whipping cream with 75 g fat, 5 g carbohydrate and 6 g protein per m² body surface) | Controlled trial | |
| Milan AM. et al., Nutrients, 2017 [ | 15 young adults (mean age 23 y, 40% men) and 15 elderly subjects (mean age 67 y, 40% men) | Plasma LPS quantified by LAL | High-fat (32% fat) or low-fat (11.5% fat) meals | Randomized crossover study | No difference in LPS levels after high-fat diet compared to baseline |
| Schmid A. et al., Br J Nutr, 2015 [ | 19 healthy subjects (mean age 42 y, all men) | Plasma LPS quantified by LAL | Three meals (High-fat dairy meal, High-fat non-dairy meal supplemented with milk or not, all 60% fat) | Randomized crossover study | |
| No difference in postprandial LPS levels between the three meals | |||||
| Moreira AP. et al., J Hum Nutr Diet, 2016 [ | 65 overweight and obese subjects (mean age 27 y, all men) | Plasma LPS quantified by LAL | Three meals (shake with conventional peanuts CVP, high-oleic peanuts HOP or control biscuit CT, all 49% fat) | Controlled trial | |
| Clemente-Postigo M. et al., J Lipid Res, 2012 [ | 10 subjects with HOMA-IR ≤ 5 and TG < 80 mg/dL (group 1, mean age 40 y), 10 subjects with HOMA-IR > 8 and TG < 80 mg/dL (group 2, mean age 39 y), 10 subjects with HOMA-IR ≤ 5 and TG > 80 mg/dL (group 3, mean age 43 y) and 10 subjects with HOMA-IR > 8 and TG > 80 mg/dL (group 4, mean age 42 y), all morbidly obese subjects | Serum LPS quantified by LAL | High-fat meal (50% fat) | Controlled trial | |
| No difference in LPS levels after high-fat diet between groups | |||||
| Deopurkar R. et al., Diabetes Care, 2010 [ | 48 healthy subjects (range age 25–47 y) | Plasma LPS quantified by LAL | 33 g dairy cream (70% SFA, no carbohydrate), 75 g glucose-based drink, orange juice or water | Controlled trial | |
| No difference in LPS levels after ingestion of glucose-based drink, orange juice or water | |||||
| Ghanim H. et al., Diabetes Care, 2009 [ | 20 healthy subjects (range age 20–50 y, 75% men) | Plasma LPS quantified by LAL | High-fat high cholesterol HFHC (42% fat) or American Heart Association (AHA)-recommended (27% fat)) meals | Controlled trial | |
| No difference in LPS levels after AHA diet compared to baseline | |||||
| Ghanim H. et al., J Clin Endocrinol Metab, 2017 [ | 10 healthy subjects (mean age 33 y, 60% men) | Plasma LPS quantified by LAL | High-fat high-carbohydrate HFHC meal (42% fat) with or without additional 30 g of fibre | Randomized crossover study | |
| No difference in postprandial LPS levels with additional 30 g of fibre to the HFHC | |||||
| Erridge C. et al., Am J Clin Nutr, 2007 [ | 12 healthy subjects (mean age 32 y), all men | Plasma LPS quantified by LAL | High-fat meal (toast with 50 g butter) | Randomized crossover study | LPS after high-fat meal |
| Laugerette F. et al., J Nutr Biochem, 2011 [ | 12 healthy subjects (mean age 27 y, all men) | Plasma LPS quantified by LAL | Mixed meal (33% fat) | Controlled trial | |
| Vors C. et al., Lipids Health Dis, 2017 [ | 8 normal-weight (mean age 29 y) and 8 obese (mean age 31 y) subjects, all men | Plasma LPS quantified by LAL | Meals with emulsified or spread fat | Randomized crossover study | |
Abbreviations: LPS Lipopolysaccharide; LAL Limulus Amebocyte Lysate; SFA Saturated fatty acids; MUFA monounsaturated fatty acids; PUFA polyunsaturated fatty acids; T2DM Type 2 Diabetes Mellitus; HOMA-IR Homeostasis model assessment of insulin resistance; TG Triglycerides; IGT impaired glucose tolerance.
Selective evidence on the association between long-term diet and endotoxemia.
| Clinical Trials | |||||
|---|---|---|---|---|---|
| Reference | Sample Characteristics at Baseline | Endotoxemia Assessment | Nutritional Assessment | Analysis Design | Results |
| Laugerette F. et al., Mol Nutr Food Res, 2014 [ | 18 healthy subjects (mean age 31 y, all men) | Plasma LPS quantified by LAL | Overfeeding with +70 g of lipids to the usual daily diet with 46.3% from saturated fatty acids during 8 weeks | Controlled trial | |
| No difference in fasting levels of LPS after overfeeding period compared to baseline | |||||
| Breusing N. et al., J Am Coll Nutr, 2017 [ | 15 healthy subjects (age 20–29 y, all men) | Plasma LPS quantified by LAL | Overfeeding (+50% of the energy requirement) during 1 week, caloric restriction (−50% of the energy requirement, 3.5% fat) during 3 weeks and hyper-caloric refeeding (+50% of the energy requirement) with either low- or high-glycemic index diet during 2 weeks | Randomized crossover study | |
| Normalization of fasting levels of LPS levels with the caloric restriction diet | |||||
| López-Moreno J. et al., J Agric Food Chem, 2017 [ | 75 subjects with metabolic syndrome (mean age 56 y) | Plasma LPS quantified by LAL | Four diets (High-saturated-fatty acids diet (HSFA, 38% fat with 16% SFA, 12% MUFA and 6% PUFA), High MUFA (HMUFA, 38% fat with 8% SFA, 20% MUFA and 6% PUFA), Low-fat high complex carbohydrate (LFHCC, 28% fat) and LFHCC n-3 supplemented with n-3 PUFA) during 12 weeks | Randomized controlled trial | |
| No difference in postprandial LPS levels after HMUFA, LFHCC and LFHCC n-3 diets | |||||
| No difference in fasting levels of LPS between all 4 groups of diet after intervention | |||||
| López-Moreno J. et al., Exp Gerontol, 2018 [ | 20 healthy subjects (mean age 67 y, 50% men) | Plasma LPS quantified by LAL | Mediterranean diet enriched in MUFA with virgin olive oil (38% fat) or SFA-rich diet (38% fat) or low-fat high-carbohydrate diet enriched in n-3 PUFA (CHO-PUFA diet, 30% fat) during 3 weeks | Randomized crossover study | |
| No difference in postprandial levels of LPS after Mediterranean diets enriched in MUFA or SFA | |||||
| Pendyala S. et al., Gastroenterology, 2012 [ | 8 healthy subjects (mean age 60 y, 38% men) hospitalized for the study | Plasma LPS quantified by a neutrophil priming method | Western-type diet (40% fat with 20.8% from saturated fat, 20% protein and 40% carbohydrates) or Prudent-type diet (20% with 5.8% from saturated fat, 20% protein and 60% carbohydrates) during 1 month | Randomized crossover study | |
|
| |||||
|
|
|
|
|
|
|
| Amar J. et al., Am J Clin Nutr, 2008 [ | 130 subjects below the LPS detection threshold (mean age 55 y), 44 subjects between 9–39 U/mL (mean age 54 y) and 27 subjects under 39 U/mL (mean age 53 y), all healthy men | Plasma LPS quantified by Kinetic-QCL TM test | 3 days of food-record diary | Cross-sectional | |
| Kallio KA. et al., Acta Diabetol, 2015 [ | 2452 subjects (mean age 52 y) | Serum LPS quantified by LAL | 24 h dietary recall | Cross-sectional | |
| No significant association between fasting levels of LPS and fat intake, and among subjects with obesity, metabolic syndrome, diabetes or coronary heart disease | |||||
| Röytiö H. et al., Br J Nutr, 2017 [ | 88 overweight pregnant women (mean age 30 y) | Serum LPS quantified by LAL | Three groups based on 3 days of food-record diary (low fibre (<25 g/j) and moderate fat intake (25–40%) n = 57, high fibre (>=25 g/j) and moderate fat intake (25–40%) n=18 and low fibre (<25 g/j) and high fat intake (>=40%) n = 13) | Cross-sectional | No significant association between fasting levels of LPS and fat intake |
| No difference in fasting levels of LPS levels among the three diet groups | |||||
| Ahola AJ. Et al., Sci Rep, 2017 [ | 668 patients with type 1 diabetes (mean age 45 y, 44% men) | Serum LPS quantified by LAL | Food frequency questionnaire and3 days of food-records diary | Cross-sectional | |
| No difference in fasting levels of LPS levels for sweet, cheese, vegetable or traditional diets | |||||
| No difference in fasting levels of LPS levels for energy, macronutrients and fibre intake | |||||
| Pastori D. et al., J Am Heart Assoc, 2017 [ | 704 patients with nonvalvular atrial fibrillation treated by vitamin K antagonists (mean age 74 y, 57% men) | Serum LPS quantified by ELISA | Short food frequency questionnaire | Cross-sectional | |
| No difference in fasting levels of LPS levels for the consumption of olive oil, vegetables, fish, wine, meat and bread | |||||
Abbreviations: AD Alzheimer’s Disease; LPS Lipopolysaccharide; LAL Limulus Amebocyte Lysate; SFA Saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids.
Selective evidence on the association between lipopolysaccharides and cognitive function.
| Clinical Trials | |||||
|---|---|---|---|---|---|
| Reference | Sample Characteristics at Baseline | Endotoxemia Assessment | Outcomes | Study Design | Results |
| Krabbe KS. et al., Brain Behav Immun, 2005 [ | 12 healthy subjects (mean age 26 y, all men) | Injection of LPS | Memory and learning (Word-list memory test) | Randomized double-blind crossover study | Negative correlation between IL-6 at 4.5 and 6 h post-injection and the word-list learning performance |
| Kullmann JS et al., Soc Cogn Affect Neurosci, 2014 [ | 18 healthy subjects (mean age 26 y, all men) | Injection of LPS | Emotional/social processing (Reading the mind in the eye) | Randomized double-blind crossover study | LPS injection did not affect the number of correct responses during the Reading the mind in the eye test |
| Grigoleit JS. et al., Neurobiol Learn Mem, 2010 [ | 24 healthy subjects (mean age 25 y, all men) | Injection of LPS | Attention and executive functions (Color word stroop task (assessment before and 1.5 h post-injection)) | Randomized double-blind controlled trial | LPS injection did not affect performance on cognitive tests |
| Grigoleit JS. et al., PLoS One, 2011 [ | 18 healthy subjects in the low-dose group (LPS 0.4 ng/kg) and 16 subjects in the high-dose group (LPS 0.8 ng/kg), mean age 25 y | Injection of LPS | Working memory (N-back task) | Randomized double-blind crossover study | |
| Moieni M et al., Brain | 109 healthy subjects (mean age 24 y, 40% men): 58 subjects in the LPS injection group and 51 in the placebo group | Injection of LPS | Emotional/social processing (Reading the mind in the eye) | Randomized double-blind controlled trial | |
| Reichenberg A. et al., Arch Gen Psychiatry, 2001 [ | 20 healthy subjects (mean age 24 y, all men) | Injection of LPS Salmonella abortus equi 0.8 ng/kg or placebo | Declarative memory (Story recall, Figure recall and Word-list learning) | Randomized double-blind crossover study | |
| Cohen O. et al., J Mol Neurosci, 2003 [ | 10 healthy subjects (sub-sample of the Reichenberg’s study [ | Injection of LPS Salmonella abortus equi 0.8 ng/kg or placebo | Declarative memory (Story recall) | Randomized double-blind crossover study | |
| Van den Boogaard M. et al., Crit Care, 2010 [ | 15 healthy subjects in the injection group (mean age 23 y, all men) and 10 healthy controls (mean age 25 y, all men) | Injection of LPS | Working memory (Digit span backward) | Single-blind trial | |
|
| |||||
|
|
|
|
|
|
|
| Lyons JL. et al., J Acquir Immune Defic Syndr, 2011 [ | 97 HIV-infected patients (mean age 47 y, 76% men) | Plasma LPS quantified by LAL | HIV-associated neurocognitive disorders (HAND) | Cross-sectional | LPS levels did not differ according to the severity of HAND |
| Vassallo M. et al., J Neurovirol, 2013 [ | 40 HIV-infected patients with HIV-associated neurocognitive disorders (HAND) (median age 46 y, 78% men) and 139 HIV-infected patients without HAND (median age 44 y, 72% men) | Plasma LPS quantified by LAL | HIV-associated neurocognitive disorders (HAND) | Cross-sectional | LPS levels was higher in the HAND group compared to no-HAND group |
| Jespersen S. et al., BMC Infect Dis, 2016 [ | 62 untreated HIV-infected patients without evidence of impaired cognitive function (mean age 39 y, 52% men) | Plasma and CSF LPS quantified by LAL | CSF neurofilament light chain protein (marker of CNS axonal damage) and CSF neopterin (marker of monocyte activation) | Cross-sectional | No association between plasma LPS and CSF neurofilament light chain protein or CSF neopterin |
Abbreviations: AD Alzheimer’s Disease; LPS Lipopolysaccharide; LAL Limulus Amebocyte Lysate; HIV Human Immunodeficiency Viruses; HAND HIV-associated neurocognitive disorders; CSF Cerebrospinal Fluid; CNS Central Nervous System; NFL Neurofilament light chain protein.
Selective evidence on the association between lipopolysaccharides and dementia.
| Alzheimer’s Disease Brain Samples | |||||
|---|---|---|---|---|---|
| Reference | Sample Characteristics at Baseline | Endotoxemia Assessment | Outcomes | Study Design | Results |
| Zhan X. et al., | 24 AD brains (mean age 77 y, 38% men, median Braak stage: 6) and 18 age-matched controls brains (mean age 81 y, 56% men, median Braak stage: 2) | LPS | Superior temporal gyrus from grey matter (GM) and frontal lobe from white matter (WM) | Cross-sectional | |
| Zhao Y. et al., | 10 AD brains (mean age 74 y) and 8 controls brains (mean age 73 y), all women | LPS | Neocortex (temporal lobe) and hippocampus | Cross-sectional | |
|
| |||||
| Zhang R. et al., J Neuroimmunol, 2009 [ | 18 AD patients (mean age 79 y, 39% men) and 18 healthy controls (mean age 55 y, 67% men) | Plasma LPS quantified by LAL | Alzheimer’s disease | Cross-sectional | |
| Ancuta P. et al., PLoS One, 2008 [ | 119 HIV patients whose 32 with No-NCI, 28 with HIV-associated dementia, 25 with MCMD, 20 with NPI-O, 9 ANI and 5 unable to assign | Plasma LPS quantified by LAL | HIV-associated dementia (HAD, defined as the involvement of at least two cognitive domains and documented by a performance of two SD below the normative mean on neuropsychological tests, with marked interference in | Cross-sectional | |
Abbreviations: AD Alzheimer’s Disease; LPS Lipopolysaccharide; LAL Limulus Amebocyte Lysate; HIV Human Immunodeficiency Viruses.